Diabetic patients are susceptible to renal ischemia-reperfusion injury, which leads to perioperative complications. Nucleotide binding and oligomerization domain (NOD)-like receptor 3 inflammasome participates in the development of diabetes, and contributes to renal ischemia-reperfusion injury. Dexmedetomidine, a highly selective α2-adrenoreceptor agonist, shows renoprotective effects against ischemia-reperfusion injury. We aimed to elucidate the effects, underlying mechanisms, and optimal timing of dexmedetomidine treatment in diabetic rats.
Introduction
Acute kidney injury (AKI) is a common complication in surgical patients and is associated with increased mortality, risk of chronic kidney disease and hemodialysis after discharge, and cost. Diabetes mellitus is a metabolic disorder with major complications including microvascular and macrovascular diseases and an important risk factor for AKI resulting in renal damage and dysfunction, as it increases susceptibility to ischemia-reperfusion (IR)
injury.[1]
Diabetic nephropathy is the leading cause of end-stage renal disease. In renal tissues of streptozotocin (STZ)-induced diabetic rats, nucleotide binding and oligomerization domain (NOD)-like receptor 3 inflammasome is activated. Suppression of NLRP3 inflammasome activation was shown to significantly reduce renal tissue inflammation and improve renal function. [2] NLRP3 knock-out mice were protected from renal tubule damage and renal interstitial inflammation in kidney unilateral ureteral occlusion and IR models. [3] These data show that NLRP3 inflammasome plays a key role in kidney IR injury.
Dexmedetomidine (DEX) is a highly selective α2-adrenoreceptor agonist with sedative, analgesic, sympatholytic, and hemodynamic stabilizing properties. Previous studies suggest that DEX has organoprotective effects, reducing cerebral and cardiac injury. [4, 5] DEX also reduced renal injury, an effect abolished by α2-adrenoreceptor antagonist atipamezole. [6] Moreover, DEX protected against kidney IR injury through anti-apoptotic, anti-inflammatory, and antioxidant effects in diabetic rats. [7] Despite clinical importance of mitigating renal damage in IR injury in surgical patients, underlying molecular mechanisms of DEX remain poorly understood.
Here, we investigate the protective effects of DEX against renal IR injury in diabetic rats and elucidate the relation between DEX and NLRP3 inflammasome. Additionally, this study attempted to identify DEX treatment regimens achieving optimal renoprotective effects in a diabetic rat renal IR injury model.
Materials and methods

Animal preparation
All animal experiments were approved by the Committee for the Care and Use of Laboratory Male Sprague-Dawley rats (60 animals, 10-12 weeks old, 250-300 g) were used. Diabetes was induced by a single intraperitoneal injection of freshly prepared STZ (85 mg/kg) dissolved in 100 mM sodium citrate buffer (pH 4.5), and operations were performed 2 weeks after STZ administration. Blood sugar concentration was determined using tail blood samples.
Rats were housed in a temperature and light-controlled animal facility with alternating 12hour light/dark cycles and ad libitum access to standard laboratory chow and water.
General anesthesia was induced using xylazine (Rompun, 10 mg/kg) and tiletamine + zolazepam (Zoletil 50, Virbac Korea, 30 mg/kg). Rats were intubated with a 16-gauge (G) catheter and artificially ventilated (Harvard Apparatus 683, Holliston, MA, USA) at [30] [31] [32] [33] [34] [35] cycles/min. The right femoral artery was cannulated to monitor mean arterial pressure (MAP) and collect blood. Heart rate (HR) was monitored by subcutaneous stainless-steel electrodes connected to the power lab system (ML845 PowerLab with ML132; AD Instruments, Colorado Springs, CO, USA). Body temperature was maintained at approximately 37 °C using a heating pad and continuously monitored throughout the experiment.
Experimental models and study groups
Rats were randomly divided (12 rats per group) into normal-sham (N-sham), diabetic-sham (D-sham), diabetic IR control (D-IRC) receiving normal saline, diabetic DEX pre-treatment-IR (D-DEXpre), and diabetic IR-DEX post-treatment (D-DEXpost) groups. We used a previously described rodent model of renal IR injury. [9] In brief, both rat renal arteries were clamped for 45 min with non-traumatic microvascular clamps followed by 24 h of reperfusion. Ischemia and reperfusion were confirmed by visually inspecting the kidneys.
MAP and HR were continuously monitored and recorded during the procedures (baseline, during ischemia, and after reperfusion). All diabetic rats underwent midline incision to expose both kidneys. To examine DEX renoprotective effects, DEX (Precedex, Pfizer, 10 µg/kg) was administered 1 h before ischemia or upon reperfusion, whereas the control group received an equivalent amount of normal saline. Initially, we tested the efficacy of various DEX doses (10, 20, 50, and 100 µg/kg) 1 h before ischemia and found that 10 µg/kg yielded optimal renoprotective effects against renal tubular damage. IR-control groups received equivalent amounts of normal saline via tail vein. Blood glucose concentration >200 mg/dl was considered high glucose level. [10] Blood glucose concentrations were determined at baseline, before ischemia, upon reperfusion, and 24 h later. Kidneys were collected after 24-h reperfusion.
Periodic acid-Schiff staining
Tissue samples for histopathological examination were taken from the left kidney (including the ischemic zone) after 24-h reperfusion, fixed in 10% buffered formalin, and embedded in paraffin. Paraffin-embedded kidney tissues were cross-sectioned through the midpoint to analyze histologic damage. Periodic acid-Schiff (PAS) staining was performed as previously described. [11] Degree of tubular damage was assessed on a scale of 1 to 4 (no histopathological findings observed, focal area of tubular necrosis involving <25% of the kidney, tubular necrosis involving 25-50% of the kidney, and tubular necrosis involving >50% of the kidney corresponding to 1-4, respectively) [11] (N=6).
TUNEL assay
Apoptosis was detected in paraffin sections from each group using the terminal deoxynucleotidyl transferase (TdT)-mediated uridine triphosphate (dUTP) nick end labeling (TUNEL) as previously described. [12] Sections (5 µm 
BUN and creatinine analysis
BUN and serum creatinine concentrations were determined 24 h after reperfusion using picric acid and diacetyl monoxime methods [13] , respectively.
Immunoblotting
Tissue samples were lysed in RIPA buffer (10 mM Tris-HCl (pH 7.5), 1 mM EDTA, 150 mM NaCl, 1% NP-40, 2% SDS, 1% sodium deoxycholate, 50 mM NaF, 0.2 mM Na 3 
Statistical analysis
Data are expressed as means ± S.D. and were analyzed using one-way analysis of variance (ANOVA) followed by Bonferroni correction or repeated measures two-way ANOVA. Pvalues <0.05 were considered significant.
Results
Hemodynamic parameters
Diabetic rats displayed increased blood glucose levels and reduced body weight. Table 1 shows hemodynamic data for all groups throughout the study period. No significant differences in MAP and HR at baseline or during ischemia were observed between groups.
MAP was increased by IR; however, post-reperfusion treatment with DEX significantly attenuated this increase (p <0.05). IR-induced HR increase was significantly attenuated in both DEX-treated groups (p <0.05). Figure 2B ). Figure 3A ). Post-reperfusion DEX treatment attenuated increase in CTP1A,
DEX reduced serum levels of IL-6 and TNF-α following IR injury in diabetic rats
DEX favorably altered expression of Bcl-2, Bax, and cleaved-
PARP in diabetic rats
NOX4, and TXNIP levels following IR in diabetic rats
Following IR, CTP1A, NOX4, and TXNIP levels were significantly increased in D-IRC group compared with D-sham group, an effect significantly reduced in DEX post-reperfusion treatment group (p <0.05, Figure 4A ).
Post-reperfusion DEX treatment decreased IR-induced increase in phospho-AKT and phospho-ERK in diabetic rats
Pre-and post-reperfusion DEX treatments ameliorated IR-induced increase in phospho-AKT and phospho-ERK compared to D-IRC group levels (p <0.05), with post-reperfusion treatment with DEX proving more effective (p <0.05, Figure 4B ). No significant difference in ASC levels was observed between diabetic rat groups ( Figure 5 ). 
Discussion
This is the first study to demonstrate that renoprotective effects of DEX in renal IR injury are associated with the inflammasome. IR injury increased the levels of inflammasome components NLRP3 and caspase-1, an effect reversible by DEX. DEX also reduced increased IL-1 levels, activated by the inflammasome. Inflammasome-associated protective effect of DEX was greater in the post-reperfusion treatment group than in the pre-treatment group.
Post-reperfusion DEX treatment had greater protective effect than pre-treatment in terms of AKT and ERK signaling, oxidative stress, and renal dysfunction.
NLRP3 inflammasome contributes to the development of type 1 and 2 diabetes mellitus. [14, 15] The inflammasome is a promising potential therapeutic target in numerous renal diseases. NLRP3 protein, the essential component of the inflammasome, contributes to renal IR injury via direct effects on renal tubular epithelium. In diabetes, hyperglycemia can activate ROS and the NLRP3 inflammasome. During IR, ROS promote tissue inflammation and activate immune responses through different pathways, including NLRP3 inflammasome. [24] Previously, TXNIP-mediated NLRP3 activation via oxidative stress was identified as a key signaling mechanism in susceptibility to AKI. [16, 25] DEX administered to diabetic rats ameliorates lipid peroxidation, oxidative stress, and IRrelated renal injury partly by inhibiting P38-MAPK (mitogen-activated protein kinases) activation and expression of TXNIP in diabetic kidney. [7, 26] In this study, DEX treatment, especially post-treatment, attenuated increase in oxidative stress markers (CTP1A, NOX4, and TXNIP) following IR.
Furthermore, increased inflammatory markers in IR injury, as expected, were diminished by DEX. In diabetes, elevated levels of circulatory pro-inflammatory factor IL-1 can induce sustained inflammation, causing kidney injury. Reperfusion of ischemic tissues increases inflammatory reactions due to an increase in the release of free radicals and accumulation of inflammatory mediators. Activation of inflammasome also produces IL-1 a proinflammatory cytokine. DEX was reported to decrease production of cytokines, including IL-1 and TNF-α, in renal IR injury model. [27] In this study, DEX treatment after IR injury improved renal protection compared to preemptive administration. Therefore, this study provides evidence of retained renoprotective efficacy of DEX under diabetic conditions against IR injury and demonstrates a large therapeutic window of these effects relative to the onset of ischemic insult. Optimal timing of DEX administration remains controversial. [4, 28] Gonullu et al. showed that DEX administered before ischemia and after reperfusion histomorphologically reduced renal IR injury, with administration of DEX during reperfusion considered more effective. [29] We speculated that because of the fast onset of effects and rapid clearing of DEX from circulation [30] , post-reperfusion treatment with DEX would be more effective in protecting against IR injury than DEX pre-treatment.
No clear recommendations regarding effective DEX dose ranges in experimental IR injury in rat models have been established. [7] However, a wide range of DEX intraperitoneal doses (10-100 g/kg) showed protective effects against ischemia or IR injury. [6, 29, 31] 
Conclusions
This study showed that protective effects of DEX in renal IR injury are preserved under diabetic conditions and related to the inflammasome. Furthermore, post-reperfusion DEX treatment was more effective than pre-ischemia treatment. These findings potentially provide a basis for using DEX in treating renal IR injury.
